A Comparison of Two Immunoassay Methods for the Measurement of Maternal Serum Placental Growth Factor in Early Pregnancy

Cowans, Nicholas J.; Kisanga, M. C.; Khan, Azmatullah; Spencer, Kevin

doi:10.1159/000336661

Cited by 3 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The method is a solid‐phase, two‐site fluorometric sandwich assay where monoclonal antibodies are directed against two separate antigenic determinants on PlGF, detecting the free form of all known PlGF isoforms commonly used for preeclampsia and trisomy 21 screening. The DELFIA method may have different specificity to the R&D Systems assay . The tracer antibody is europium (Eu) labeled, from which Eu‐N3 chelate complexes form after addition of DELFIA inducer solution, which are measured by the AutoDELFIA fluorescence reader.…”

Section: Methodsmentioning

confidence: 89%

See 1 more Smart Citation

First trimester maternal serum placental growth factor levels in twin pregnancies

Cowans

Spencer

2013

Prenatal Diagnosis

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 89%

“…The DELFIA method may have different specificity to the R&D Systems assay. 10 The tracer antibody is europium (Eu) labeled, from which Eu-N3 chelate complexes form after addition of DELFIA inducer solution, which are measured by the AutoDELFIA fluorescence reader. PlGF standards were run in duplicates, whereas samples were run in singleton.…”

Section: Methodsmentioning

confidence: 99%

First trimester maternal serum placental growth factor levels in twin pregnancies

Cowans

Spencer

2013

Prenatal Diagnosis

View full text Add to dashboard Cite

show abstract

“…Likewise, in the second trimester, PLGF has also been found to be increased, 23 decreased, 24 and unchanged 25,26 in cases of trisomy 21. However, these inconsistencies in the literature may be due to which immunoassay methods were used to measure PLGF as mentioned in the article by Cowans et al 27 In our study, we focused primarily on the effects of adding PLGF for the detection of trisomy 21 and we found a large variation between DR for a given FPR across studies as a poor fit of the model. Also, our analysis reveals average improves trisomy 21 DRs between 1.4 and 3.3% for FPRs between 5 and 1%, respectively.…”

Section: Discussionmentioning

confidence: 89%

“…Likewise, in the second trimester, PLGF has also been found to be increased, 23 decreased, 24 and unchanged 25 26 in cases of trisomy 21. However, these inconsistencies in the literature may be due to which immunoassay methods were used to measure PLGF as mentioned in the article by Cowans et al 27 …”

Section: Discussionmentioning

confidence: 99%

Use of Placental Growth Factor for Trisomy 21 Screening in Pregnancy: A Systematic Review

Badeghiesh

Volodarsky‐Perel

Lasry

et al. 2020

AJP Rep

View full text Add to dashboard Cite

Background Prenatal serum screening is an important modality to screen for aneuploidy in pregnancy. The addition of placental growth factor (PLGF) to screen for trisomy 21 remains controversial. Objective To determine whether the addition of PLGF to combined serum aneuploidy screening improves detection rates (DRs) for trisomy 21. Study Design We performed a systematic review of the literature until October 2019 to determine the benefits of adding PLGF to prenatal screening. We performed a goodness-of-fit test and retrieved the coefficient of determinations (R 2) as a function of false positive rates (FPRs), providing mean-weighted improvements in the DRs after accounting for PLGF levels. Results We identified 51 studies, of which 8 met inclusion criteria (834 aneuploidy cases and 105,904 euploid controls). DRs were proportional to FPR across all studies, ranging from 59.0 to 95.3% without PLGF and 61.0 to 96.3% with PLGF (FPR 1–5%). Goodness-of-fit regression analysis revealed a logarithmic distribution of DRs as a function of the FPR, with R 2 = 0.109 (no PLGF) and R 2 = 0.06 (PLGF). Two-sample Kolmogorov–Smirnov's test reveals a p-value of 0.44. Overall, addition of PLGF improves DRs of 3.3% for 1% FPR, 1.7% for 3% FPR, and 1.4% for 5% FPR, respectively. Conclusion Addition of PLGF to prenatal screening using serum analytes mildly improves trisomy 21 DRs as a function of FPRs.

show abstract

“…Although both platforms quantify isoform 1 of PlGF, their absolute concentration results differ when samples are tested in parallel, as has been noted previously between PlGF assay platforms. 285 Possible explanations for this difference include the manual process of the Alere Triage versus the automated DELFIA Xpress platform, the possibility of the platforms measuring cross-reactive PlGF isoforms and bound verse unbound PlGF to different degrees. 285 Nevertheless, the findings add to the growing body of research which indicates that both pre-labour hemodynamic evidence of suboptimal fetal growth 138,260,261 and subtle placental dysfunction 271 are already evident in apparently low-risk pregnancies and that this predisposes these apparently normally grown babies to CS-IFC, Op-IFC and CNO.…”

Section: Discussionmentioning

confidence: 99%

Prediction of fetal distress

Bligh¹

View full text Add to dashboard Cite

Introduction: Identification of the increased risk of intrapartum fetal compromise prior to labour is an obstetric challenge. Globally, intrapartum hypoxia remains a major contributor to stillbirth, hypoxic ischemic encephalopathy and cerebral palsy. For parents and families, the psychosocial and financial impact ($1.5 billion in Australia) of these complications are profound and long-lasting. The majority of these catastrophic events occur despite a lack of obvious risk factors. Objectives: To explore the relationship between feto-placental and feto-maternal Doppler ultrasound variables and maternal serum placental growth factor (PlGF) concentration with adverse perinatal outcomes (caesarean for intrapartum fetal compromise, CS-IFC; operative delivery of any kind for intrapartum fetal compromise, Op-IFC; or composite neonatal outcome, CNO) in low risk pregnancies from 36 weeks' gestation. Additionally, to determine the screening performance of these variables. Methods: A prospective, observational, panel study of low risk women was conducted at Mater Mothers' Hospital, Brisbane. Women were eligible to participate if they were normotensive with an appropriately grown singleton fetus, uncomplicated pregnancy and anticipating a vaginal delivery beyond 36 weeks' gestation. Women underwent fortnightly assessment of various feto-placental and feto-maternal Doppler parameters, estimated fetal weight and maternal PlGF quantification. Maternal characteristics, ultrasound and PlGF data, intrapartum and neonatal outcomes were recorded. For each assessment and for the last assessment preceding delivery, ultrasound and PlGF variables were assessed for their distribution and association with outcomes. Additionally, the rate of change in the individual variables was tested for association with outcomes for the different gestation intervals at assessment. Finally, the screening performance of ultrasound and PlGF parameters were tested in isolation and combination for raw and gestation-adjusted (regression and centiles) variables. Results: From May 2014 to September 2016, 483 women participated in the study, with exclusions predominantly for missing data and planned cesarean delivery. For the Doppler parameters, the following associations were demonstrated: the umbilical artery pulsatility index (PI) was higher at 40 weeks' gestation for babies in the adverse Op-IFC outcome group; the middle cerebral artery PI was lower in the adverse outcome groups for CS-IFC (40 weeks' gestation), Op-IFC (36, 38, 40 weeks' gestation and last assessment) and CNO (last assessment) groups; the cerebroplacental ratio was lower in the adverse outcome groups for CS-IFC (40 weeks' gestation and last assessment), Op-IFC (38 and 40 weeks' gestation and last assessment) and CNO (40 weeks' gestation and last assessment); weight-adjusted umbilical venous flow rate was lower in the adverse outcomes groups for CS-IFC iv (38 weeks' gestation), Op-IFC (38 weeks' gestation and last assessment) and CNO (last assessment); the uterine artery PI was higher in the ...

show abstract

A Comparison of Two Immunoassay Methods for the Measurement of Maternal Serum Placental Growth Factor in Early Pregnancy

Cited by 3 publications

References 44 publications

First trimester maternal serum placental growth factor levels in twin pregnancies

First trimester maternal serum placental growth factor levels in twin pregnancies

Use of Placental Growth Factor for Trisomy 21 Screening in Pregnancy: A Systematic Review

Prediction of fetal distress

Contact Info

Product

Resources

About